Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palliative radiotherapy combined with immune checkpoint inhibitors for previously treated advanced gastric cancer
ChiCTR2500102619Phase 2Not yet recruiting
- Sponsor
- Central Hospital Affiliated to Shandong First Medical University
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab and nivolumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Central Hospital Affiliated to Shandong First Medical University. Primary endpoint: Overall survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
sintilimabnivolumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500102619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102619.